Hereditary Angioedema

CTAF

ICER will assess the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The report is expected to focus on four therapies for the prevention of hereditary angioedema attacks: lanadelumab (Shire), which is currently under review by the FDA with an approval decision expected in August of 2018, and three C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire; and Ruconest®, Pharming). This list is tentative and subject to change.

Associated Meetings

October 25, 2018 10am-4pm PT

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of therapies for hereditary angioedema.

Key Dates

Associated Materials

03/23/2018 – 04/09/2018
Open Input Period
04/12/2018

Open to public comment until May 2, 2018. For more information about submitting a public comment, including formatting specifications, please see our engagement page.

Draft Scoping Document
04/12/2018
Stakeholder List
04/12/2018 – 05/02/2018
Public Comments
05/10/2018
Revised Scoping Document
06/29/2018
Model Analysis Plan
08/21/2018
Draft Voting Questions
08/21/2018 – 09/18/2018
Public Comments
08/21/2018
Draft Evidence Report
10/11/2018
Revised Voting Questions
10/11/2018
Evidence Report
10/11/2018
Response to Comments
10/25/2018
Meeting Agenda
10/25/2018
Evidence Presentation
11/15/2018
Final Evidence Report and Meeting Summary